Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 3/20 | 0.41 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bicarbonate SCHEMBL8082241 | 0.93 | MAPT (0.57) | MAPTKDM4EALDH1A1CYP1A2CA12 | |
| Oxalic Acid SCHEMBL7825836 | 0.91 | MAPT (0.56) | MAPTKDM4EALDH1A1CYP1A2CA12 | |
| Carbamic Acid SCHEMBL28412507 | 0.89 | MAPT (0.54) | MAPTKDM4EALDH1A1CYP1A2CA12 | |
| Indoline SCHEMBL17652456 | 0.89 | DRD2 (0.44) | MAPTKDM4EALDH1A1CYP1A2MAPK1 | |
| Benzene SCHEMBL29053622 | 0.89 | MAPT (0.50) | MAPTKDM4EALDH1A1CYP1A2CA12 | |
| Urea SCHEMBL28255233 | 0.87 | MAPT (0.51) | MAPTKDM4EALDH1A1CYP1A2CA12 | |
| SCHEMBL29370549 | 0.87 | MAPT (0.50) | MAPTKDM4EALDH1A1CA12CA1 | |
| SCHEMBL18172 | 0.87 | MAPT (0.50) | MAPTKDM4EALDH1A1CA12CA1 | |
| SCHEMBL27392334 | 0.87 | MAPT (0.50) | MAPTKDM4EALDH1A1CA12CA1 | |
| Fumaric Acid SCHEMBL7722940 | 0.86 | MAPT (0.51) | MAPTKDM4EALDH1A1CYP1A2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109071786-B | Two part curable composition | 汉高知识产权控股有限责任公司 | 2021-09-14 | — | — | CN | disclosed |
| US-10689504-B2 | Two part curable composition | Henkel IP & Holding GmbH (DE) | 2020-06-23 | — | — | US | disclosed |
| CN-106715559-B | Curing accelerators for anaerobic curable compositions | 汉高知识产权控股有限责任公司 | 2020-02-28 | — | — | CN | disclosed |
| EP-3436500-A1 | TWO PART CURABLE COMPOSITIONS | Henkel IP & Holding GmbH (DE) | 2019-02-06 | — | — | EP | disclosed |
| US-20190023872-A1 | TWO PART CURABLE COMPOSITION | HENKEL AG & CO. KGAA (DE) | 2019-01-24 | — | — | US | disclosed |
| US-9969690-B2 | Cure accelerators for anaerobic curable compositions | Henkel IP & Holding GmbH (DE) | 2018-05-15 | — | — | US | disclosed |
| WO-2017172270-A1 | TWO PART CURABLE COMPOSITIONS | Henkel IP & Holding GmbH (DE) | 2017-10-05 | — | — | WO | disclosed |
| EP-3201266-A1 | CURE ACCELERATORS FOR ANAEROBIC CURABLE COMPOSITIONS | Henkel IP & Holding GmbH (DE) | 2017-08-09 | — | — | EP | disclosed |
| US-20170174630-A1 | CURE ACCELERATORS FOR ANAEROBIC CURABLE COMPOSITIONS | HENKEL AG & CO. KGAA (DE) | 2017-06-22 | — | — | US | disclosed |
| WO-2016054124-A1 | CURE ACCELERATORS FOR ANAEROBIC CURABLE COMPOSITIONS | Henkel IP & Holding GmbH (DE) | 2016-04-07 | — | — | WO | disclosed |
| EP-1425015-A4 | TETRAHYDROQUINOLINE DERIVATIVES AS ANTITHROMBOTIC AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2004-12-15 | — | — | EP | disclosed |
| US-6825208-B2 | SELECTIVE INHIBITORS OF SERINE PROTEASE ENZYMES, ESPECIALLY FACTOR VIIA; MODULATION OF THE COAGULATION CASCADE. | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-11-30 | — | — | US | disclosed |
| EP-1425015-A2 | TETRAHYDROQUINOLINE DERIVATIVES AS ANTITHROMBOTIC AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-06-09 | — | — | EP | disclosed |
| US-20030225110-A1 | Tetrahydroquinoline derivatives as antithrombotic agents | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-12-04 | — | — | US | disclosed |
| WO-2003015715-A2 | TETRAHYDROQUINOLINE DERIVATIVES AS ANTITHROMBOTIC AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-02-27 | — | — | WO | disclosed |
| WO-1998025884-A1 | FURTHER ANTHRAQUINONES WITH BIOLOGICAL ACTIVITY | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1998-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225110-A1 | Tetrahydroquinoline derivatives as antithrombotic agents | TFPI, TFPI2, SERPINC1 | MAPT 4276/4885KDM4E 2375/4885ALDH1A1 2602/4885 |
| US-20170174630-A1 | CURE ACCELERATORS FOR ANAEROBIC CURABLE COMPOSITIONS | AHCY, AHCYL1, CAPG | MAPT 4449/4885KDM4E 193/4885ALDH1A1 1098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.